KRAS and cancer: Pan-KRAS inhibitors, such as the one described here, merit clinical testing in patients as they stand to affect the clinical outcomes of patients with KRAS-driven cancers, including those with lung, colorectal and pancreatic cancer as well as further less-frequent cancer types.